RADX FY2026 EPS Estimate Cut by Brookline Capital Management

Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) – Brookline Capital Management lowered their FY2026 earnings per share (EPS) estimates for Radiopharm Theranostics in a research report issued on Monday, December 15th. Brookline Capital Management analyst K. Dolliver now expects that the company will post earnings per share of ($2.30) for the year, down from their prior forecast of ($2.25). Brookline Capital Management also issued estimates for Radiopharm Theranostics’ FY2027 earnings at ($2.43) EPS.

Other equities analysts have also recently issued reports about the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Radiopharm Theranostics in a research report on Wednesday, October 8th. B. Riley restated a “buy” rating and set a $16.00 target price (up previously from $13.00) on shares of Radiopharm Theranostics in a research note on Tuesday. Two analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $15.33.

Radiopharm Theranostics Price Performance

RADX stock opened at $5.19 on Thursday. Radiopharm Theranostics has a 1-year low of $3.50 and a 1-year high of $16.25. The business’s 50 day simple moving average is $5.19 and its 200 day simple moving average is $5.25.

Institutional Investors Weigh In On Radiopharm Theranostics

An institutional investor recently raised its position in Radiopharm Theranostics stock. PNC Financial Services Group Inc. increased its stake in shares of Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) by 100.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,000 shares of the company’s stock after buying an additional 8,000 shares during the quarter. PNC Financial Services Group Inc. owned about 0.20% of Radiopharm Theranostics worth $88,000 at the end of the most recent reporting period.

Radiopharm Theranostics Company Profile

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.